Prognostic value of circulating H3K27Me3-nucleosomes in newly diagnosed lung cancer patients
Authors:
- Aristotelis KotronoulasAKAristotelis Kotronoulas
- Emmanuel GrolleauEGEmmanuel Grolleau
- Julie CandiracciJCJulie Candiracci
- Gaelle LescuyerGLGaelle Lescuyer
- Laurent VilleneuveLVLaurent Villeneuve
- Michael DuruisseauxMDMichael Duruisseaux
- Patrick MerlePMPatrick Merle
- Sébastien CouraudSCSébastien Couraud
- Marielle HerzogMHMarielle Herzog
- Marie PiecykMPMarie Piecyk
Preprint
- 2 June 2026
- preprint
- Published by Springer Nature in Research Square
Abstract
Lung cancer remains a leading cause of cancer-related mortality, with heterogeneous outcomes, underscoring the need for robust prognostic biomarkers. Circulating tumor DNA (ctDNA) enables detection of actionable mutations and may provide prognostic information; however, many patients lack detectable alterations, limiting its utility for molecular-based risk stratification. We analyzed plasma from 617 treatment-naïve patients using targeted next-generation sequencing for ctDNA and immunoassays to quantify circulating H3K27Me3-nucleosomes. Survival analyses included 514 patients with ≥8-month follow-up. Elevated H3K27Me3-nucleosome levels were independently associated with poorer overall survival. Patients with levels <56 ng/mL had significantly longer survival than those with higher concentrations (26 vs 12 months; p<0.0001), including in ctDNA-negative patients (29 vs 12 months; p<0.0001). A multivariable Cox model integrating H3K27Me3, stage, mutation, and age showed good performance (C-index 0.80) and was validated in an independent cohort. Circulating H3K27Me3-nucleosomes enable clinically relevant risk stratification at diagnosis, supporting more precise patient management in lung cancer.Keywords
All Related Versions
This publication has 45 references indexed in Scilit:
- Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancerCancer Treatment Reviews, 2024
- A metabolomics pipeline highlights microbial metabolism in bloodstream infectionsCell, 2024
- Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancerClinical and Translational Oncology, 2024
- Current challenges and practical aspects of molecular pathology for non-small cell lung cancersVirchows Archiv, 2023
- DNA and histone modifications as potent diagnostic and therapeutic targets to advance non-small cell lung cancer management from the perspective of 3P medicineEPMA Journal, 2022
- ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiencesCritical Reviews in Oncology/Hematology, 2022
- A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer's disease dementiaAlzheimer's & Dementia, 2022
- Dementia risk in the general population: large-scale external validation of prediction models in the AGES-Reykjavik studyEuropean Journal of Epidemiology, 2021
- Survival patterns in lung and pleural cancer in Europe 1999–2007: Results from the EUROCARE-5 studyEuropean Journal of Cancer, 2015
- Chromatin Modifications and Their FunctionCell, 2007